<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809587</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/026612</org_study_id>
    <nct_id>NCT01809587</nct_id>
  </id_info>
  <brief_title>IQP-PO-101 for the Regulation of Bowel Movement Frequency</brief_title>
  <official_title>Open Label Study to Assess the Safety and Efficacy of IQP-PO-101 in Regulating Bowel Movement Frequency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of IQP-PO-101 in regulating
      the bowel movement frequency
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel movement frequency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Subjects will keep a record of the number of bowel movements, if any, from 00:00 hours to 23:59 hours (midnight to midnight) daily.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Form Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Subjects will keep a record of their stool form, for each bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Straining at the start/ end of defecation</measure>
    <time_frame>6 weeks</time_frame>
    <description>On a 100mm visual analogue scale (VAS), subjects will rate their feeling of straining at the start/ end of defecation for each bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during defecation</measure>
    <time_frame>6 weeks</time_frame>
    <description>On a 100mm visual analogue scale (VAS), subjects will rate their pain during defeca-tion for each bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeling of incomplete evacuation</measure>
    <time_frame>6 weeks</time_frame>
    <description>With each bowel movement, subjects will mark &quot;Yes&quot; or &quot;No&quot; to indicate whether there was a feeling of incomplete evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of efficacy by subjects</measure>
    <time_frame>4 weeks</time_frame>
    <description>The subjects evaluate independently the efficacy of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of efficacy by investigator</measure>
    <time_frame>4 weeks</time_frame>
    <description>The investigator evaluates independently the efficacy of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
    <time_frame>4 weeks</time_frame>
    <description>Venous blood samples are obtained at screening and the end of the treatment period (4 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry</measure>
    <time_frame>4 weeks</time_frame>
    <description>Venous blood samples are obtained at screening and the end of the treatment period (4 weeks) for measurements of uric acid, HbA1c and lipid profiles. An analysis will be done based on the change between the 2 periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation by subjects</measure>
    <time_frame>4 weeks</time_frame>
    <description>The subjects evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation by investigators</measure>
    <time_frame>4 weeks</time_frame>
    <description>The investigators evaluate independently the safety of the investigational device (global scaled evaluation with &quot;very good&quot;, &quot;good&quot;, &quot;moderate&quot; and &quot;poor&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Constipation</condition>
  <condition>Irregular Bowel Movement Frequency</condition>
  <arm_group>
    <arm_group_label>IQP-PO-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQP-PO-101</intervention_name>
    <arm_group_label>IQP-PO-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject must have experienced 2 - 4 bowel movements per week and at least 2 of the
             following symptoms over the preceding 3 months (self-reported):

               -  Excessive straining

               -  Lumpy or hard stools

               -  Sensation of anorectal obstruc-tion

               -  A sense of incomplete evacua-tion of bowel movements

               -  A need for digital manipulation to facilitate evacuation

          -  Recorded between 4 and 9 defecations in the 14-day bowel movement diary during the
             run-in period

          -  Subjects of childbearing potential must agree to use appropriate contraceptive methods
             during run-in and treatment period

          -  Commitment to avoid the use of any laxatives and/ or other medicinal products/
             supplements that may interfere with bowel movement frequency during the run-in and
             treatment period

          -  Written informed consent.

        Exclusion Criteria:

          -  Known sensitivity to the ingredients of the device

          -  Any organic gastrointestinal diseases, congenital or otherwise

          -  Presence of occult blood on screening

          -  Constipation that may have been drug-induced

          -  Use of any laxative/ products that help ease bowel movements within 7 days of the
             screening visit

          -  Constipation other than idiopathic constipation

          -  Presence of other factor(s) that, in the in-vestigator's judgement, should preclude
             subject participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Analyze &amp; Realize Ag</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

